<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807909</url>
  </required_header>
  <id_info>
    <org_study_id>CV010-005</org_study_id>
    <nct_id>NCT02807909</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects</brief_title>
  <official_title>An Open-Label Single-Sequence Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-Dose Pharmacokinetics of BMS-986177 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to assess the effects of co-administration of itraconazole or
      diltiazem, respectively, on the pharmacokinetic (PK) parameters Cmax, AUC(INF), and AUC(0-T)
      of BMS-986177
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC (0-T)) of BMS-986177</measure>
    <time_frame>Days 1-12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Days 1-12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))</measure>
    <time_frame>Days 1-12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and death</measure>
    <time_frame>Screening- until 30 days after discontinuation of dosing or subject's participation in the study if the last scheduled visit occurs at a later time.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>BMS-986177 and Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose BMS-986177 on day 1 followed by Itraconazole and BMS-986177 on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986177 and Diltiazem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose BMS-986177 on day 1 followed by Diltiazem ER and BMS-986177 on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986177</intervention_name>
    <arm_group_label>BMS-986177 and Itraconazole</arm_group_label>
    <arm_group_label>BMS-986177 and Diltiazem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <arm_group_label>BMS-986177 and Itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem ER</intervention_name>
    <arm_group_label>BMS-986177 and Diltiazem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent

          2. Target population: Healthy subjects as determined by medical history, surgical
             history, physical examination, vital signs, electrocardiogram (ECG), and clinical
             laboratory determinations.

          3. Subjects with body mass index of 18 to 30 kg/m2, inclusive

          4. Men, and women of nonchildbearing potential. Women must have documented proof that
             they are not of childbearing potential and are not breast feeding

          5. Males who are sexually active with women of childbearing potential (WOCBP) must agree
             to follow instructions for method(s) of contraception for the duration of treatment
             with study drug(s) plus 5 half-lives of the study drug (3 days) plus 90 days (duration
             of sperm turnover) for a total of 92 days for subjects in the BMS-986177 - diltiazem
             sequence, and 99 days for subjects in the BMS-986177 - itraconazole sequence.

        Exclusion Criteria:

          1. Any significant acute or chronic medical illness, including hepatic disease, or any
             other condition listed as a contraindication in the diltiazem or itraconazole package
             inserts.

          2. Evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or
             frequent unexplained bruising or thrombus formation.

          3. History of chronic constipation, GI disease, arrhythmias, sinus bradycardia,
             significant head injury, dizziness or headaches, hemophilia, Rosenthal syndrome, or
             FX1a deficiency or other coagulopathies, systemic lupus erythematosus.

          4. Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG, or clinical laboratory determinations beyond
             what is consistent with the target population

          5. History of allergy to BMS-986177, itraconazole, diltiazem, or related compounds.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/studyconnect/pages/home.aspx</url>
    <description>Description BMS Clinical Trial Education Resource</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>Description FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Description Investigator Inquiry Form</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>September 9, 2016</last_update_submitted>
  <last_update_submitted_qc>September 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

